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 This study was designed to provide an immunohistochemical 
analysis of tumor biological factors in 28 patients who un-
derwent hepatectomy for cholangiocellular carcinoma 
(CCC). Analyzed factors were microvessel counts (stained by 
CD34) and proliferating cell nuclear antigen (PCNA). PCNA 
L.I. was correlated with serum level of CA19-9, which was 
correlated with a higher recurrence rate and shorter pa-
tient survivals. Microvessel counts were negatively corre-
lated with tumor size. Furthermore, the microvessel count 
in CCC with mass-forming (MF) plus periductal infiltrating 
(PI) type associated with poorer survivals, was significantly 
lower compared to that of CCC with MF type or PI type. 
Neither microvessel counts nor PCNA L.I. were associated 
with any other clinicopathologic factors or cancer recur-
rence. The five-year overall and cancer-free survival rates 
were 26% and 13%, respectively. Patients with MF plus PI 
type, poorer differentiated carcinoma, stage 4A and higher 
CA19-9 level had shorter cancer-free and overall survivals 
after hepatectomy (p<0.05). Cancer-free and overall surviv-
als in patients with lower microvessel counts tended to be 
slightly worse but were not significantly different. Although 
tumor microvessel count and proliferating activity were 
correlated with prognostic clinicopathologic parameters, 
both factors might not be prognostic markers for predict-
ing CCC recurrence and patient survival. 
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Introduction
 Hepatic resection is the most appropriate option for 
radical treatment of intrahepatic cholangiocellular car-
cinoma (CCC). However, the recurrence rate and the 
rate of cancer-related death after resection remain 
high." Although the conventional clinicopathological 
factors such as a tumor morphology in CCC may be 
related to shorter patient survival, 2'') accurate predic-
tion of prognosis in CCC is not currently possible. The 
examination of differences in tumor biological charac-
teristics may provide useful information about the ac-
tivity of CCC. It has been previously reported that 
imicr o vessel. counts that show angiogeinesis and the 
proliferation activity of cancer cells were significantly 
related with malignant behavior and poor prognosis in 
patients with liver cancers.'-" A combination of con-
ventional clinicopathologic factors and such tumor 
biological factors may improve predictions of progno-
sis after hepatectomy for CCC. 
 In the present study, we examined both the expres-
sion of microvessel counts by using CD34 and the 
proliferative activity by using proliferating cell nu-
clear antigen (PCNA) labeling index in CCC using 
immunohistochemical stains. Using those figures, we 
investigated the relationship between their expression 
in CCC, the clinicopathological factors and patient 
prognosis after hepatic resection.
Materials and Methods
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Patients
 Specimens of CCC from 28 patients were obtained dur-
ing surgery on patients who were admitted to the Division 
of Surgical Oncology, Department of Translational
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Medical Sciences, Nagasaki University Graduate 
School of Biomedical Sciences (the previous First 
Department of Surgery, Nagasaki University School of 
Medicine) between January 1994 and December 2002. 
The mean age of the patients at the time of surgery 
was 63.4 ± 10.2 years (range: 44-82 years), and they 
comprised 16 males and 12 females. Prior to surgery 
for CCC, patients were treated with neither chemother-
apy nor radiation. After surgery, two patients (7.1%) 
received adjuvant oral chemotherapy using 5-
fluorouracil analog (UFTTM: Tegafur and Uracil at a 
molar ratio of 1:4, Taiho Pharmaceutical Co., Ltd., 
Tokyo, Japan). Twenty-three patients (82.1%) had 
tumor recurrence after hepatectomy. The operative 
procedures included lobectomy or extended lobectomy 
(n=20), segmentectomy or subsegmentectomy (n=5) 
and partial resection (n=3). The study design was ap-
proved by the Ethics Review Board of our department 
and a signed consent was obtained from each patient. 
 We used the classification system of the General Rules 
for the Clinical and Pathological Study Of Primary Liver 
Cancer." This system provides a clinicopathological 
evaluation and macroscopic classification of CCC. 
  The minimum follow-up period after hepatic resec-
tion of CCC was 12 months. Radical hepatectomy was 
performed to remove the hepatic tumor without leav-
ing any residual tumor. All hepatic tumors were com-
pletely resected without macroscopic exposure of the 
amputated section to the remaining liver. 
  Resected specimens were fixed in 10% for malin and 
embedded in paraffin. Thin sections (4,a m) were 
deparaffinized twice by xylene and rehydrated in a se-
ries of ethanol solutions (100, 90 and 80%).
reagent using labeled streptavidin-biotin (LSAB) kit' 
Peroxidase (Dako). The peroxidase reaction was visual-
ized with 0.01% H202 and 3,3'-diaminobenzidine using 
a light microscope (x200).
Evaluation and statistical analysis
 The average percentage of positive nuclear PCNA 
expression in 1,000 nuclei in five areas of the tumor 
was estimated. With the microvessel count using 
CD34 staining, we determined the average count in 
the five most vascular areas examined at x200 magni-
fications' CD34 expression was evaluated in the sur-
rounding areas of tumor. In the periductal-infiltrating 
(PI), the mass forming (MF) and the intraductal 
growth (IG) type," the stained cells were counted in 
the marginal area of tumor. In the MF plus PI type, 
the stained cells were counted in the marginal area of 
MF tumor. 
 For the univariate analysis, categorical data were 
analyzed by the chi-square test or Fisher's exact test. 
The disease-free interval and the overall survival were 
calculated according to the Kaplan-Meier method, and 
the differences between the groups were tested for 
significance using the log-rank test. The continuous 
variables, such as the microvessel count and PCNA 
expression, were classified into two groups based on 
the median values for analyzing patient survivals. A 
two-tailed P value of < 0.05 was considered signifi-
cant. StatlSticai analyses were per for i1 1e d with using 
the computer software STATISTICATM (StatSoft, Tulsa, 
OK).
Immunohistochemical staining
 Sections were placed in 0.01 M trisodium citrate de-
hydrate buffer (pH 6.0) and treated in a microwave 
oven for 10 min at 500 watts. For CD34 staining," 
the tissue sections were digested with 0.2% trypsin in 
0.01 M phosphate-buffered saline (PBS) for 20 min at 
37'C. In the next step, the tissues were immersed in 
3% H202 with distilled water for 10 min to inactivate 
endogenous peroxidases. After blocking non-specific 
binding by normal goat serum, sections were incu-
bated either overnight at 4 °C with mouse anti-
monoclonal CD34 antibody (1:25 dilution; QB-END/10, 
Novocastra Laboratories, Newcastle, UK), or for 1 hour 
at room temperature with monoclonal mouse anti-
proliferating cell nuclear antigen (PCNA) antibody 
(1:100; PC-10, Dako Co., Carpinteria, CA) as the pri-
mary antibody, respectively. This was followed by re-
action with biotinylated anti-immunoglobulin and
Results
Relationship between expression of CD34 and PCNA la-
beling index (L.L), and clinicopathological features 
 The median values of microvessel counts by using 
CD34 in surrounding tissues of the tumor area were 
106 ± 33/mm3. The median values of PCNA in CCC 
cells were 14.9±7.8%. Table 1 shows the relationship 
between the expression of these molecules and the 
clinicopathological features in CCC. The microvessel 
count and PCNA L.I. were not correlated with patient 
age. The recurrence rate of patients with the higher 
CA 19-9 levels (>100 U/ml) (14/14; 100%) was signifi-
cantly higher than that of the patients with the lower 
CA 19-9 levels (8/14; 57%) (p=0.021). PCNA L.I. was 
positively correlated with a serum level of CA 19-9. 
The microvessel count was negatively correlated with 
tumor size. Both microvessel counts and PCNA L.I
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were correlated with neither liver function tests nor 
the degree of hepatic fibrosis. 
 In these patients, the recurrence rate in patients
Table 1. Correlation between microvessel counts and prolifer-
ating activity in the tumor , and clinicopathological factors 
in cholangiocellular carcinomas.
               CD34 (/mm3) a PCNA (%)' 
Age -0.184 0.386 
CEA(ng/ml)` -0.177 -0.210 
CA] 9-9 (U/ml) d 0.066 0.502' 
Tumor size (cm) -0.582' 0.262 
1CG R15 (%) e 0.320 -0.078 
LHL 15' -0.179 0.279 
Fibrotic scores 0.301 -0.300
aMicrovessel counts in the surrounding tissue of CCC
, bProliferating activity in CCC, 
carcinoembryonic antigen, d sialyl Lewisa antigen, ' indocyanine green retention rate at 15 
minutes, `liver activity at 15 minutes by technetium-99m galactosyl human serum 
albumin scintigraphy,' Staging score for hepatic fibrosis defined by Knodell et al.,24 6 
p=0.0014,'p=0.034
Table 2. Relationship between microvessel counts and 
proliferating activity, and clinicopathologic factors in 
cholangiocarcinoma.
                             CD34 (/mm') PCNA (%) 
Gender 
 Male (n=16) 114±32 18.3±5.1 
 Female (n=12) 92±29 14.7±4.6 
Macroscopic classification a 
 Intraductal growth type (n=2) 113±33 16.5±2.7 
 Mass-forming type (MF) (n=9) 125±97 14.9±6.4 
 Periductal infiltrating type (PI) (n=3) 139±35 10.4±8.1 
 MF+PI type (n=14) 86±25 c 15.6±9.1 
Intrahepatic metastases 
 No (n=18) 103±29 16.3±7.3 
 Yes (n=10) 103±34 11.8±9.3 
Lymph ode metastases 
 No (n=15) 102±32 15.0±8.9 
 Yes (n=13) 108±34 14.9±7.4 
Serosal invasion 
 No (n=18) 106±30 13.2±8.6 
 Yes (n=10) 104±38 17.2±6.3 
Histopathological differentiation 
 Well (n=6) 116±31 13.1±8.1 
 Moderate-poor (n=22) 103±36 15.8±8.2 
Pathological TNM stage b 
   1, TI (n=4) 125± 7 15.1± 4.8 
  III (n=8) 100±32 14.5± 9.1 
  IVA (n=3) 69±13 16.8± 5.5 
  IVB (n=13) 108±33 14.9± 7.4 
Recurrence 
 No (n=5) 119±23 13.7± 8.4 
 Yes (n=23) 103±34 15.3± 7.9
'Classification of Primary Liver Cancer 7
, b the General Rules for the Clinical and 
Pathological Study Of Primary Liver Cancer 7 c) p=0.008 vs. MF or PI type
with the PI type, and the MF plus PI type (3/3; 100% 
and 14/14; 100%, respectively) was significantly higher 
than that in patients with the MF type or the IG type 
(6/9; 67% and 0/2;0%, respectively) (p=0.0024). The 
microvessel count in CCC with MF plus PI type was 
significantly lower than that of CCC with MF type or 
PI type (Table 2). However, neither the microvessel 
count nor PCNA L.I. were associated with any other 
clinicopathologic factors and cancer recurrence. 
Relationship between biological factors in CCC and sur-
vival after hepatic resection 
 Among 28 patients in the present study, the cancer-
free 1-, 3- and 5-year cancer-free survival rates were 
41%, 26% and 26%, respectively, and the median can-
cer-free survival period was 2.1 years. The overall 1-, 
3- and 5-year survival rates were 48%, 29% and 13%, 
respectively, and the median overall survival period 
was 1.8 years. By the univariate analysis, patients with 
PI type and MF plus PI type by the macroscopic clas-
sification, poorer differentiated carcinoma, stage 4A 
and higher CA 19-9 level (>100 U/ml) had the shorter 
cancer-free and overall survivals after hepatectomy in 
the present series (p<0.05). Figure 1 shows the cancer-
free and overall patient survivals after hepatectomy 
for each parameter. The cancer-free and overall sur-
vivals in patients with lower microvessel counts 
tended to be slightly worse but were not significant
  (A) 
 100 CD34 100 PCNA 
                          <100/mm3 <15%
   80 > 100/mm, . 80 L ........... >15% 
  60 P=0.375 NS 60 P=0.839 NS 
a 40 MS: 982 days MS: 942 days                                 40 
................. .201 MS: 443 days 20 MS: 585 days 
: ................................................ 
U U 
  0 0 
   0 1000 2000 3000 0 10,00 2000 300( 
          Time after hepatectomy (days) Time after hepatectomy (days)
 (B) 
 100 CD34 100 PCNA 
                           <100/mm, <15%
                                             0 80 -- >15%
IE- >_ loo/mm3 
                          P=0.525 NS 
60 P=0.692 NS 
        
i MS: 770 days 
. . . . . . . . . . . . . . . . . . . . . . . 
                                 40 
                                                        MS:1167 days
O 20 MS: 548 days O 20 .................................. 
                                                           MS:736 days
  0 0 
   0 1000 2000 3000 0 1000 2000 3000 
            Time after hepatectomy (days) Time after hepatectomy (days)
Figure 1. Cancer-free (A) and overall (B) survivals for pa-
tients who underwent hepatic resection for cholangiocellular 
carcinomas. Relationship between microvessel counts and 
proliferation activity of the tumor, and survivals. MS: Mean 
survival period.
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differences. PCNA L.I. was associated with neither can-
cer-free nor overall survivals.
Discussion
  Patient prognosis in cholangiocarcinoma is quite 
poor because of the tumor aggressiveness and high in-
cidence of lymph node metastases."'," The rate of 
curative surgical resection is low and patient survival 
after hepatectomy is still poor.""""' By questionnaire 
investigation at the conference of Nagasaki Hepato-
Biliary-Pancreas surgery (Nagasaki Kan-Tan-Sui Geka 
Kenkyukai, Nagasaki, 1997), the median survival pe-
riod after hepatic resection in 56 Nagasaki patients 
with CCC was 18.2 months and the 3- and 5-year cu-
mulative survival rates were 10% and 4%, respectively. 
According to the recent reports, the UICC's tumor-
node-metastasis (TNM) classification system, surgical 
margin, serum CA 19-9 level, histological differentiation 
and macroscopic classification are related with progno-
sis in CCC patients who undergo radical hepatectomy at 
present.'"" 
 The recent studies of CCC have revealed the candi-
date tumor biological factors by using advanced methods 
for detecting genetic abnormalities such as DNA ploidy 
pattern,") the reduced expression of keratin 903'5' or p2 
716' and the overexpression of MUC-11" 1171, MMP-7"' or 
cyclin D1.19' We believe that clarifying the relationship be-
tween such factors and patient prognosis should con-
tribute to future classification criteria for CCC. In the 
present study, we performed an immunohistochemical 
study using two markers: microvessel count (as a 
marker of angiogenesis) and PCNA labeling index (as 
a marker of proliferation) on the basis of previous 
studies on other solid tumors.' - 6 ""21) These markers 
were closely associated with tumor aggressiveness. 
From the results of metastatic liver tumors in our pre-
vious studies, the microvessel count was very a reli-
able parameter in predicting patient prognosis. 5 ) 
Aggressive cancers may have higher proliferating ac-
tivities. To our knowledge, these parameters concern-
ing patient survival have not been fully examined in 
CCC. 
 In the present study, the microvessel counts of CCC 
in larger tumors were lower. CCC usually shows mar-
ginal enhancement and central hypo-vascularity on 
enhanced imaging. With an increase in tumor size, the 
fibrous tissue components become increased in the 
tumor and, therefore, vascularity may reduce. The 
microvessel counts in CCC with MF plus PI type were 
lower compared to other types. Previous reports and 
the present results showed that patient survivals with
CCC showing MF plus PI type are significantly poor.10' 
Therefore, despite the fact that its mechanism remains 
unknown, the reduced vascularity of CCC may be as-
sociated.. with tumor aggressiveness. We speculate that 
hypovascular tumors may be resistant to the anti-
cancer drugs or host immune responses. In our pre-
liminary study, hepatocellular carcinoma with lower 
microvessel count was also associated with poor pa-
tient survival by multivariate analysis (submitted but 
unpublished). The PCNA labeling index (L.I.) of carci-
nomas was correlated with serum CA 19-9 level in the 
present study. CA 19-9 is a sensitive marker for pan-
creatic and biliary carcinomas, which reflect the ma-
lignant behavior of tumors.") Serum CA 19-9 level in 
patients with CCC may be correlated with tumor pro-
liferation activity. Ohashi et al. reported that PCNA 
L.I. in periductal- or specula-forming type of CCC was 
significantly higher than that in mass-forming type."' 
They suggested that macroscopic classification of CCC 
reflect the proliferating activity or invasiveness of the 
tumor. In the present study, there was no significant 
difference of PCNA L.I. between each macroscopic 
type. PCNA L.I. in CCC remained the same from the 
early to the advanced stages of tumor and, therefore, 
tumor cells of CCC might already have malignant po-
tential at the early stage. 
 With respect to patient survival after hepatectomy," 2, 6," 
the results of our series were similar. The previous 
studies showed higher TNM stage,"","' tumor except 
intrad'uctai growth type, 2 ' 5 , 13' higher C A 19-9 ie v ei, l 1' 
less differentiation") and less curability of surgical 
resection 5,7,11,11' to be associated with poor survival in 
patients with CCC, in agreement with our present se-
ries. Many tumors showing MF or PI type revealed 
the higher tumor stage, although some patients with 
stage IV had longer survival.2.71 It is thus necessary 
to clarify cellular characteristics showing tumor ag-
gressiveness except conventional clinicopathologic pa-
rameters by the new approach. Our results showed 
that the mean survival period in patients with lower 
microvessel counts tended to be slightly shorter but the 
difference was not statistically significant. Although 
this factor might have been slightly associated with 
tumor aggressiveness and patient survival, the roles of 
tumor vascularity were not predominant. The patho-
genesis of CCC is complicated and the various biologi-
cal factors could have important relations with malig-
nant behavior of CCC. A future study using other 
biological markers should be expected to clarify the 
aggressiveness of CCC. 
 In conclusion, we have demonstrated that hypovascularity 
of CCC was associated with tumor size and macroscopically 
invasive type while, on the other hand, proliferation
Atsushi Nanashima et al : Tumor Biological Factors in Cholangioma
activity of CCC was correlated with serum CA 19-9 
level. Neither vascularity nor proliferation activity of 
CCC were significantly associated with the prognosis 
of patients undergoing hepatic resection. Determination 
of other biological factors will be necessary for evalu-
ating the prognosis of patients who undergo surgical 
resection of cholangiocarcinoma in the next step.
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